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ABSTRACT
Due to therapeutic challenges, hospital-acquired infections (HAIs) caused by Acinetobacter baumannii (HA-AB), particularly
carbapenem-resistant strains (HA-CRAB) pose a serious health threat to patients worldwide. This systematic review
sought to summarize recent data on the incidence and prevalence of HA-AB and HA-CRAB infections in the WHO-
defined regions of Europe (EUR), Eastern Mediterranean (EMR) and Africa (AFR). A comprehensive literature search was
performed using MEDLINE, EMBASE and GMI databases (01/2014-02/2019). Random-effects meta-analyses were
performed to determine the pooled incidence of HA-AB and HA-CRAB infections as well as the proportions of
A. baumannii among all HAIs. 24 studies from 3,340 records were included in this review (EUR: 16, EMR: 6, AFR: 2). The
pooled estimates of incidence and incidence density of HA-AB infection in intensive care units (ICUs) were 56.5 (95%
CI 33.9-92.8) cases per 1,000 patients and 4.4 (95% CI 2.9-6.6) cases per 1,000 patient days, respectively. Five studies
conducted at a hospital-wide level or in specialized clinical departments/wards (ICU + non-ICU patients) showed HA-
AB incidences between 0.85 and 5.6 cases per 1,000 patients. For carbapenem-resistant A. baumannii infections in
ICUs, the pooled incidence and incidence density were 41.7 (95% CI 21.6-78.7) cases per 1,000 patients and 2.1 (95%
CI 1.2-3.7) cases per 1,000 patient days, respectively. In ICUs, A. baumannii and carbapenem-resistant A. baumannii
strains accounted for 20.9% (95% CI 16.5-26.2%) and 13.6% (95% CI 9.7-18.7%) of all HAIs, respectively. Our study
highlights the persistent clinical significance of hospital-acquired A. baumannii infections in the studied WHO regions,
particularly in ICUs.
ARTICLE HISTORY Received 4 October 2019; Revised 21 November 2019; Accepted 21 November 2019
KEYWORDS Acinetobacter baumannii; hospital-acquired infections; healthcare-acquired infections; nosocomial infections; carbapenem resistance
Introduction
Acinetobacter spp. are non-fermenting, largely opportu-
nistic Gram-negative bacteria that are ubiquitous in the
environment.Acinetobacter baumannii complex (Acine-
tobacter nosocomialis, Acinetobacter pitti and Acineto-
bacter baumannii) are the most clinically significant
out of the over 50 species in the Acinetobacter genus
[1]. Of all Acinetobacter species, A. baumannii sensu-
stricto (shortened to A. baumannii) is responsible for
about 90%of the clinical infections caused byAcinetobac-
ter spp. in humans [1]. Infections from A. baumannii, in
particular carbapenem-resistant A. baumannii (CRAB),
are of significant public health importance worldwide
because of their association with high treatment costs,
mortality andmorbidity [2,3]. TheWorldHealthOrgan-
ization (WHO) has ranked carbapenem-resistant
A. baumannii as a critical priority pathogen on its global
priority list of antibiotic-resistant bacteria to guide drug
research and development [4]. Worldwide, CRAB has
been implicated in several hospital outbreaks of diseases
like pneumonia, bloodstream, wound and urinary tract
infections, especially amongpatients with severemorbid-
ities such as those staying in ICU [5,6]. The pathogen is
able to survive adverse environmental conditions, foster-
ing its persistence and spread in the hospital environment
[7,8]. Treating carbapenem-resistant A. baumannii
infections is very challenging since they are naturally
resistant to antibiotics in the WHO “Access” and
“Watch” list. They are therefore associated with poor
clinical outcomes across many healthcare settings [9].
Multiple studies have been conducted worldwide to
analyses the burden of healthcare-associated infections
caused by A. baumannii. Depending on the variables
under study (e.g. study location, included patient
cohorts and clinical wards), the incidence or prevalence
estimates of (carbapenem-resistant) A. baumannii vary
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significantly between the different studies. Even though
representative data are scarce, there is evidence for
increasing incidence of A. baumannii outbreaks in
healthcare facilities across Sub-Saharan Africa and East-
ernMediterranean countries, both of which have diverse
populations [10,11]. Moreover, the epidemiological situ-
ation has worsened in Europe as it has become endemic
in the south and eastern parts of Europe with some areas
experiencing cross-border transmission [1].
To our knowledge, no systematic review on the fre-
quency of (carbapenem-resistant) A. baumannii across
Europe, the Eastern Mediterranean Region and Africa
has been published. A comprehensive understanding
of the current epidemiological picture is therefore
needed. This systematic review aims to comprehensively
analyse recent data on the prevalence and incidence of
hospital-acquired infections with (carbapenem-resist-
ant) A. baumannii to better understand the current epi-
demiology in theseWHO-defined regions. This will help
with the development of context-specific prevention and
control interventions against this dangerous and
increasingly untreatable pathogen.
Materials and methods
This systematic review was registered in the Prospec-
tive Register of Systematic Reviews (PROSPERO; regis-
tration no. CRD42019124503) and conducted using
the PRISMA checklist [12].
Search strategy
In order to identify recent studies on the burden of hos-
pital-acquired A. baumannii infections, we performed
a systematic literature search using the electronic data-
bases MEDLINE, EMBASE, and The Global Index
Medicus (GIM) for studies from January 2014 up to
February 2019. For the search strings, we used a com-
bination of synonyms of hospital-acquired infections
and Acinetobacter baumannii (see additional file 1).
Title and abstract screening and full text review of
potentially eligible studies were carried out indepen-
dently by two researchers (R. M. and O. A.). All discre-
pancies regarding the inclusion were resolved through
discussion.
Inclusion / exclusion criteria
We included epidemiological studies that provide data
on the prevalence and/or incidence of HA-AB and HA-
CRAB infections, regardless of whether the studies
were retrospective or prospective. Studies were eligible
if they reported relevant data from patient cohorts
from entire hospitals or individual clinical depart-
ments/wards without selection of particular diseases
or patient sub-groups. Studies were only included if
they were conducted in the following WHO regions:
African Region (AFR), Eastern Mediterranean Region
(EMR) and European Region (EUR). A study was eli-
gible if it provided a clear distinction between
A. baumannii infections acquired in the hospital and
community. Only studies written in English, German
and French were eligible. Since this systematic review
focused on recent epidemiological A. baumannii data,
studies published before 2014 and studies that com-
pleted data collection before 2009 were excluded.
Studies with any of the following study design/study
type were excluded: Reviews, systematic reviews, edi-
torials, letters, commentaries, conference abstracts,
case reports, case–control studies and randomized con-
trolled trials (RCTs). Studies were excluded if no clear
distinction was made between A. baumannii infection
and colonization status.
Data extraction and outcomes of interest
Two authors (R. M. and O. A.) independently extracted
data using a standard extraction form. Any discrepan-
cies were resolved through discussion. The primary
outcome was the prevalence and/or incidence of
hospital-acquired (carbapenem-resistant) A. baumannii
infections among (i) all patients in the hospital or indi-
vidual departments/wards and (ii) among all hospital-
acquired infections (HAIs). The prevalence refers to
the number of HA-(CR)AB cases per 1,000 patients
present in the hospital or ward at a given time point.
The incidence refers to the number of new cases
acquiring a HA-(CR)AB infection per 1,000 patients
followed-up for a defined period of time. Other pri-
mary outcome parameters of interest were incidence
density and population-based estimates of HA-AB
and HA-CRAB infections. Secondary outcomes were
attributable mortality and/or lethality as well as mor-
bidity of HA-AB and HA-CRAB infections. A case of
A. baumannii infection was categorized as “carbapenem-
resistant” when stated so by the authors of the study
or when carbapenem resistance data of A. baumannii
isolates were provided in the studies. If antimicrobial
susceptibility testing showed resistance for at least one
carbapenem (such as meropenem, imipenem), the iso-
late was categorized as carbapenem-resistant. In addition
to the a priori analysis plan outlined in the study protocol,
we also performed subgroup analyses, stratifying countries




Risk of bias assessment and statistical analysis
All included studies were assessed for risk of bias by
two review authors (R.M. and O.A.). Disagreements
were resolved through discussion. The risk of bias
tool developed by Hoy et al. was used, which is specific
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for the study designs of the included studies [13]. In
order to calculate pooled incidences and incidence den-
sities, raw proportions were logit transformed [14]. For
all analyses, random-effects models with inverse var-
iance weighting were used. The I2 statistic was used
to estimate inter-study heterogeneity. All statistical
analyses and forest plots visualizations were performed
using R version 3.5.1 [15] with the “meta” (v. 4.9.5) and
“metafor” (v. 2.1.0) packages.
Results
In total, 3,340 records were identified through our
database search. Following screening of titles and
abstracts, 178 potentially eligible studies were ident-
ified and included for full text review. Finally, 24
studies published between 2014 and 2018 were
found eligible and therefore included in this systema-
tic review (Figure 1).
Study characteristics and risk of bias assessment
The study characteristics are summarized in Table 1.
Among the 24 included studies, 16 were conducted in
the European region of the WHO. Of these, eight
studies were carried out in Turkey. Six out of 24
studies were conducted in the Eastern Mediterranean
region and two in the African region. The majority of
studies were from upper-middle income (n = 11) and
high income (n = 8) countries. Two studies reported
prevalence data and 22 studies provided data on the
incidence and/or incidence density of hospital-
acquired A. baumannii infections. Just over half of
the included studies (n = 13) were conducted exclu-
sively on intensive care units (ICU). Five studies
reported hospital-level data, while six studies were
carried out in other wards or specialized clinic
departments where both ICU and non-ICU patients
are seen. The majority of studies (n = 16) also
reported data on hospital-acquired infections with
carbapenem-resistant A. baumannii. None of the
included studies provided data on population-based
incidence/prevalence or attributable mortality and
morbidity.
Overall, risk of bias was low, as judged by the risk
of bias tool by Hoy et al. (additional File 2, additional
Fig.1) [13]. This is partly explained because, as per
protocol, only epidemiological studies that included
largely unselected patient cohorts from whole hospi-
tals or individual departments/wards were eligible.
The majority of studies (19 out of 24) used criteria
from the Centers for Disease Control and Prevention
/ National Healthcare Safety Network (CDC/NHSN)
or European Centre for Disease Prevention and Con-
trol (ECDC) to define hospital-acquired infections.
The CDC/NHSN and ECDC definitions of HAIs are
widely used and validated tools in the surveillance
of healthcare-acquired infections. However, except
for three multicenter studies that provided nationally
representative estimates, the country representative-
ness was unclear or was not met in the majority of
the included studies.
Incidence of hospital-acquired Acinetobacter
baumannii infections
Based on data from 18 studies, the overall pooled
incidence of hospital-acquired A. baumannii infec-
tions (HA-AB) in the WHO regions of Europe,
Eastern Mediterranean and Africa is 25.1 (95% CI
12.8-48.5) cases per 1,000 patients (Figure 2). How-
ever, the I2 statistics indicates considerable statistical
heterogeneity between the studies. In particular, inci-
dence estimates differed substantially between studies
that were conducted exclusively in intensive care
units and studies that additionally included data
from non-intensive care units. The pooled incidence
of HA-AB infections in ICUs is 56.5 (95% CI 33.9-
92.8) cases per 1,000 ICU patients. It is important
to note that the between-study variation (I2 = 99%,
p < 0.01) was also substantial within the ICU-based
study set. Further analyses revealed no statistically
Figure 1. Study selection flowchart.
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significant differences in ICU-based rates of HA-AB
infections between the EUR and EMR WHO regions
(61.4 [95% CI 33.9-100.9] vs. 42.8 [95% CI 18.0-98.4],
Q = 0.47, p = 0.495). In addition, no differences in the
incidence of ICU HA-AB infections were observed
across country income levels (high income [four
studies], upper-middle income [seven studies] and
lower-middle income countries [two studies], Q =
0.43, p = 0.8076).
Compared to ICU-based estimates, incidences for
HA-AB infections were up to 10 times smaller in
three studies conducted in specialist clinical depart-
ments/wards where both ICU and non-ICU patients
were seen. In these studies, HA-AB incidences ranged
between 3.1 and 5.6 per 1,000 patients (pooled esti-
mate: 4.2 [95% CI 2.7-6.6] per 1,000 patients). With a
pooled incidence of 0.97 (95% CI 0.53-1.8) per 1,000
patients, the lowest HA-AB infection incidences were
observed in hospital-wide studies.
Six studies reported data on the incidence density of
hospital-acquired A. baumannii infections on ICUs
expressed as HA-AB cases per 1,000 patient days.
The pooled estimate was 4.4 (95% CI 2.9-6.6) HA-AB
cases per 1,000 ICU patient days (Figure 3). The indi-
vidual study estimates ranged from 2.8 to 6.8 HA-AB
cases per 1,000 ICU patient days, with a considerably
high inter-study heterogeneity (I2 = 96%, p < 0.01).
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Figure 2. Forest plot of studies on the incidence of hospital-acquired Acinetobacter baumannii infections. Abbreviations: HA-AB:
hospital-acquired Acinetobacter baumannii, ICU: intensive care unit, 95% CI: 95% confidence interval.
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density of 0.16 (95% CI 0.14-0.19) HA-AB infections
per 1,000 patient days, which was markedly lower
than the ICU estimates.
Incidence of hospital-acquired carbapenem-
resistant Acinetobacter baumannii infections
Twelve studies provided data on the incidence of hos-
pital-acquired infections with carbapenem-resistant
A. baumannii (HA-CRAB). The pooled incidence of
HA-CRAB cases was 21.4 (95% CI 11.0-41.3) cases
per 1,000 patients in the EUR, EMR and AFR WHO
regions (Figure 4). Estimates of HA-CRAB incidences
were substantially higher in studies exclusively con-
ducted on ICUs compared to hospital-wide studies or
studies carried out in specialist clinical departments
with ICU and non-ICU patients. The pooled incidence
of HA-CRAB infections in ICUs was 41.7 (95% CI
21.7-78.7) cases per 1,000 ICU patients, although a
considerably high inter-study variation was observed
(I2 = 99%, p < 0.01). Much lower HA-CRAB infection
rates were observed in one hospital-wide study (2.0
[95% CI 0.49-7.8] cases per 1,000 admissions) and in
two studies conducted in specialist clinical departments
Figure 4. Forest plot of studies on the incidence of hospital-acquired carbapenem-resistant Acinetobacter baumannii infections.
Abbreviations: HA-CRAB: hospital-acquired carbapenem-resistant Acinetobacter baumannii, ICU: intensive care unit, 95% CI: 95%
confidence interval.
Figure 3. Forest plot of studies on the incidence density of hospital-acquired Acinetobacter baumannii infections. Abbreviations:
HA-AB: hospital-acquired Acinetobacter baumannii, ICU: intensive care unit, 95% CI: 95% confidence interval
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for ICU and non-ICU patients (pooled estimate: 2.3
[95% CI 1.2-4.6] cases per 1,000 patients). Since eight
out of nine studies were conducted in Europe, it was
not possible to meaningfully compare ICU-based
HA-CRAB incidences between the WHO regions.
However, we found that ICU HA-CRAB incidences
tended to be higher in upper-middle income countries
(five studies, 55.8 cases per 1,000 ICU patients [95% CI
15.6-180.3]) than in high income countries (three
studies, 20.6 cases per 1,000 ICU admissions [95% CI
10.7-39.0]), although the difference was not statistically
significant (Q = 1.90, p = 0.1681). When compared to
the pooled ICU HA-CRAB incidence from high
income countries, the one study from a lower-middle
income country (Morocco) [33] was markedly higher
(80.9 cases per 1,000 ICU patients [95% CI 65.3-99.9]).
Five studies provided data on the incidence density
of hospital-acquired carbapenem-resistant A. baumannii
infections on ICUs. The pooled estimate was 2.1
(95% CI 1.2-3.7) HA-CRAB cases per 1,000 ICU
patient days (Figure 5), with individual study estimates
ranging between 0.63 and 5.4 cases per 1,000 patient
ICU days. A considerable inter-study variation was
observed (I2 = 96%, p < 0.01). The study by Atilla
et al. 2015 [44] which was conducted on a specialist
burn unit with both ICU and non-ICU patients
reported an incidence density of HA-CRAB infections
of 3.5 per 1,000 patient days.
Proportions of hospital-acquired Acinetobacter
baumannii infections among all healthcare-
acquired infections
21 incidence studies reported the proportion of
A. baumannii as a causative agent for hospital-acquired
infections. The pooled estimate of the proportion of
A. baumannii associated infections among all HAIs
was 15.3% (95% CI 11.7-19.7%) (Figure 6). Similar to
the analyses described above, the burden of
A. baumannii was especially high in intensive care
units, where A. baumannii infections accounted for
20.9% (95% CI 16.5-26.2%) of all hospital-acquired
infections, although considerable inter-study variation
was observed (I2 = 96%, p < 0.01). In studies conducted
in specialist clinical departments/wards comprised of
ICU and non-ICU patients, the pooled estimate of
the proportion of HA-AB infections among all HAIs
was 16.3% (95% CI 8.0-30.5%). However, a large var-
iance and inter-study variation (I2 = 98%, p < 0.01)
was found. As reported by three studies conducted at
hospital-wide level, A. baumannii was responsible for
1.6% to 6.2% of all HAIs (pooled estimate: 5.3% [95%
CI 3.2-8.6%]). In one study conducted solely on an
internal medical ward, A. baumannii was identified
as the causative pathogen in 1.6% of all HAIs. Although
the proportion of HA-AB among all HAIs on ICUs
observed in the EUR WHO region was about twice
as large as in the EMR WHO region, the difference
was not statistically significant (23.6% [95% CI 17.0-
31.8%] vs. 12.0% [95% CI 2.8-38.8%], Q = 1.03, p =
0.310). Furthermore, no significant differences in the
proportion of HA-AB among all HAIs in the ICU
were found among country income levels (high income
[four studies], upper-middle income [six studies] and
lower-middle income countries [two studies], Q =
1.40, p = 0.4972).
Thirteen studies reported data on the proportion of
carbapenem-resistant A. baumannii infections among
all hospital-acquired infections (Figure 7). In ICUs,
the pooled proportion of HA-CRAB infections
among all HAIs was 13.6% (95% CI 9.7-18.7%). How-
ever, a large inter-study variation was observed (I2 =
97%, p < 0.01), with individual estimates ranging
from 2.9% to 45.7%. There is evidence that the pro-
portion of HAIs due to CRAB was much lower outside
ICUs, as reported in one hospital-wide study and
Figure 5. Forest plot of studies on the incidence density of hospital-acquired carbapenem-resistant Acinetobacter baumannii infec-
tions. Abbreviations: HA-CRAB: hospital-acquired carbapenem-resistant Acinetobacter baumannii, ICU: intensive care unit, 95% CI:
95% confidence interval.
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another conducted on an internal medical ward. Both
studies found that 1.6% of all HAIs were caused by car-
bapenem-resistant A. baumannii. No comparison of
WHO regions was performed since only one study
from the AFR WHO region and none from the EMR
WHO region were included in this subgroup analysis.
Interestingly, in studies conducted in upper-middle
income countries (n = 5) the proportion of HA-
CRAB infections among all HAIs in the ICU was mark-
edly higher compared to studies (n = 3) from high
income countries (21.9% [95% CI 16.2-28.9%] vs.
8.8% [95% CI 4.8-15.6%], Q = 7.77, p = 0.0053).
Prevalence of hospital-acquired A. baumannii
infections
Two multicenter hospital-wide point prevalence
studies were included in this review that reported preva-
lences of 3.0 and 10.6, respectively, hospital-acquired
A. baumannii infections per 1,000 patients. Interestingly,
while Ahoyo et al. 2014 (Benin) [36] observed no
infections with carbapenem-resistant A. baumannii,
Kritsotakis et al. 2017 (Greece) [40] found that among
all hospital-acquired A. baumannii infections, 92%
were carbapenem-resistant, resulting in a HA-CRAB
prevalence of 8.9 per 1,000 patients.
Both studies also provided hospital-wide data on the
proportion of A. baumannii among all pathogens caus-
ing hospital-acquired infections. Kritsotakis et al. 2017
[40] reported that A. baumannii was responsible for
10.7% of all HAIs. In contrast, Ahoyo et al. 2017 [36]
identified A. baumannii as the causative pathogen in
only 1.3% of all HAIs.
Discussion
Hospital-acquired infections caused by Acinetobacter
baumannii, particularly carbapenem-resistant strains,
are a significant threat to health and patient safety
worldwide as a result of the continuing decline in
treatment options. This study is the first systematic
review and meta-analysis to provide a comprehensive
Figure 6. Forest plot of studies on the proportion of hospital-acquired Acinetobacter baumannii infections among all hospital-
acquired infections. Abbreviations: HAI: hospital-acquired infections, HA-AB: hospital-acquired Acinetobacter baumannii, ICU: inten-
sive care unit, 95% CI: 95% confidence interval.
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summary of recent data on the incidence and preva-
lence of nosocomial infections with (carbapenem-
resistant) Acinetobacter baumannii in the WHO-defined
regions of Europe, Africa and the Eastern Medi-
terranean. Based on a review of 24 included studies
published between 2014 and 2018, we show that
hospital-acquired infections caused by Acinetobacter
baumannii represent a significant risk to health for
hospital patients in Europe, Africa and Eastern
Mediterranean regions.
Importantly, the incidence of hospital-acquired AB
infections is particularly high in ICUs, where the
pooled estimate is as high as 56 HA-AB cases per
1,000 ICU patients and the pooled incidence density
is 4.4 HA-AB cases per 1,000 patient ICU days. Due
to vulnerable patients with severe comorbidities and
high number of invasive procedures, ICUs are known
hotbeds for healthcare-acquired infections, including
Acinetobacter species [49,50]. Our analyses showed
that there are no systematic differences in the incidence
of hospital-acquired A. baumannii infections in ICUs
between the European and the Eastern Mediterranean
WHO regions. It is important to note that our Euro-
pean study set is over-represented by countries located
in the south-eastern part of the European WHO
region. However, studies conducted in Italy and Poland
found similar ICU incidence when compared to studies
in Bosnia–Herzegovina, Turkey and countries from the
EMR WHO-region.
In addition to the high incidence of HA-AB infec-
tions in ICUs, we found that the pooled incidence of
carbapenem-resistant A. baumannii infections is 42
HA-CRAB cases per 1,000 ICU patients, with individ-
ual study estimates ranging between 7 and 213 cases
per 1,000 ICU patients. In comparison, a recent sys-
tematic review reported incidences of 18–649 HA-
CRAB cases per 1,000 ICU patients in Southeast Asia
[51]. Importantly, the pooled HA-CRAB incidence
observed in our study is only slightly lower than the
total incidence of HA-AB infections, suggesting that
the majority of hospital-acquired A. baumannii infec-
tions on ICUs are caused by carbapenem-resistant
strains. This finding is particularly concerning since
therapeutic options to treat CRAB infections are lim-
ited and these infections are generally associated with
high morbidity, mortality and treatment costs [2,3,52].
Not surprisingly, our study provides evidence that
the incidence and prevalence of HA-AB infections is
10–50 times lower in hospital-wide studies compared
to ICU-based studies. Two studies from Benin [36]
and Greece [40] showed prevalence of 3 and 10.6 AB
infections per 1,000 patients, respectively. In compari-
son, large multicenter studies from the United States
and China reported prevalences of 0.7 HA-AB cases
Figure 7. Forest plot of studies on the proportion of hospital-acquired carbapenem-resistant Acinetobacter baumannii infections
among all hospital-acquired infections. Abbreviations: HAI: hospital-acquired infections, HA-CRAB: hospital-acquired carbape-
nem-resistant Acinetobacter baumannii, ICU: intensive care unit, 95% CI: 95% confidence interval.
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[53] and 3.2 HA-AB cases [54] per 1,000 patients,
respectively. Moreover, evidence from a very recent
study also shows that the prevalence of carbapenem-
non-susceptible Acinetobacter spp. in the United States
(0.3 cases per 1000 admissions) is lower than in the
WHO-regions analysed in this study [55].
The prominent role of hospital-acquired
A. baumannii infections in ICUs is underlined by our
finding that A. baumannii is the causative pathogen
in more than 20% of all nosocomial infections. In
fact, as shown by several large studies in our study
set, A. baumannii is the most frequent organism to
be responsible for nosocomial infections in the ICU,
with higher infection rates than other clinically relevant
pathogens, such as K. pneumoniae, E. coli and S. aureus
[16,25,34]. This high proportion of A. baumannii-
associated HAIs on ICUs is also found in other parts
of the world, including Southeast Asia [56–58], China
[59] and Latin America [60]. In addition, a review
that examined studies between 1995 and 2008 from
low and middle income countries also found that
19% of all HAIs are caused by Acinetobacter spp. in
intensive care, and burn and transplant units [61]. In
contrast, healthcare-acquired infections with Acineto-
bacter spp. are less prevalent on ICUs in the United
States, where only 1.1% of all HAIs on ICUs are caused
by Acinetobacter spp. [62]. According to 2016 data
from The European Surveillance System (TESSy), Aci-
netobacter spp. causes only 2 - 8% of HAIs in ICUs [63]
in Europe; profoundly less than our estimates. These
discrepancies may be explained by the fact that many
Western and Northern European countries provide
data on hospital-acquired infections in TESSy, while
in our analysis studies from countries in these regions
were disproportionately under-represented. TESSy
data show that Acinetobacter spp. cause more HAIs
in ICUs in eastern and southern countries compared
to countries in northern and western regions of
WHO-Europe. It is interesting that studies providing
hospital-wide incidence estimates show that
A. baumannii causes only 1.6 - 6% of all hospital-
acquired infections compared to 20% in the ICU
(Figure 2). Other pathogens such as S. aureus and
E. coli are more frequently found among hospital-
acquired infections on a hospital-wide level than
A. baumannii, as shown by several studies in Europe
and Africa [37,38,42]. In comparison to our data, a
large multicenter study including 52 hospitals found
that 7.9% of all HAIs in China are caused by
A. baumannii [54]. Interestingly, while our data indi-
cate similar proportions of HA-AB infections among
all HAIs between high (22%) and upper-middle
(25%) income countries, we observed that HA-CRAB
proportions among all HAIs are much lower in high
income countries (9%) compared to upper-middle
income countries (22%). These findings suggest that
carbapenem resistance proportions of A. baumannii
are much higher in the ICU in countries with upper-
middle income emphasizing the clinical relevance of
HA-CRAB in the ICU of middle income countries.
There is a general dearth of recent studies investigating
the burden of (carbapenem-resistant) Acinetobacter bau-
mannii infections in the African WHO region. However,
available evidence suggests the widespread prevalence of
carbapenemase-producing bacteria in Africa, with preva-
lence ranging from 2.3% to 67.7% in North Africa, and
from 9% to 60% in sub-Saharan Africa [64]. Studies to
delineate the magnitude and spread of A. baumannii
infections across Africa are therefore urgently needed.
In addition, the Eastern Mediterranean region is affected
by several difficulties that are complicating issues around
the spread and control of antimicrobial resistance (AMR)
[65]. It is not surprising that the burden of AMR and
CRAB in particular remains high in this region, as ident-
ified in studies including our own [10].
Strength and limitations
With 24 included studies and data from more than
280,000 hospitalized patients, our systematic review
represents the largest study on the incidence and
prevalence of hospital-acquired infections from (carba-
penem-resistant) A. baumannii in the European, Afri-
can and Eastern Mediterranean WHO regions. A
major strength of our study is that we only included
studies comprising of non-disease-specific patients
from whole hospitals or individual wards, which
ensured the representativeness of our estimates for
these institutions and wards. However, our study has
some limitations. Firstly, the country representative-
ness of the individual studies is unclear in most cases,
which limits the external validity of our findings. Sec-
ondly, studies are not evenly distributed across the
WHO regions. In particular, the WHO EUR study
set is over-represented by studies from Turkey, while
no studies from western and northern parts of Europe
were included. Consequently, possible differences in
(CR)AB incidence and prevalence between the EUR
and EMR WHO regions may be masked by the geo-
graphical proximity of Turkey to the Eastern Mediter-
ranean WHO region. Thirdly, due to the relatively low
number of hospital-wide studies, our hospital-wide
estimates of hospital-acquired A. baumannii infections
are unlikely to be generalizable. Finally, we observed a
large inter-study heterogeneity, particularly within the
ICU study set, and the pooled effect sizes must there-
fore be interpreted with caution. Likely reasons for
the large inter-study variations are differences in the
distribution of underlying diseases among the included
patient cohorts, surgical procedures, immune status
and mechanical ventilation. These factors are associ-
ated with an increased risk of hospital-acquired infec-
tions [66]. Differences in environmental prevalence
and colonization rates by Acinetobacter spp., both of
1756 O. Ayobami et al.
which are understudied, may also affect HA-AB and
HA-CRAB infection rates. In addition, we also recog-
nize that it is difficult to adequately compare outcomes
of pathogen-identification tests and antimicrobial sus-
ceptibility tests carried out across various regions due
to non-standardization of definitions, infection sources
and laboratory methods.
Conclusion
Our study stresses the relevance of hospital-acquired
infections caused by A. baumannii, including infections
with carbapenem-resistant strains, in the European,
African and Eastern Mediterranean WHO regions. In
particular, the evidence provided in our systematic
review highlights the prominent role of A. baumannii
as an “ICU pathogen”, particularly in light of the high
carbapenem-resistant rates observed in most of the
included studies. This finding can guide ICUs to prior-
itize their allocation of resources for infection preven-
tion and control, and in the stewardship of antibiotics,
particularly those on the WHO’s Essential Antibiotics
Watch and Reserve categories [67].
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